Last update 04 Nov 2024
Rituximab biosimilar (Chia-tai Tianqing)
Last update 04 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Rituximab Biosimilar (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.), 利妥昔单抗生物类似药（Chia Tai Tianqing Pharmaceutical Group Co., Ltd.）, TQB 2303 + [2] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Rituximab biosimilar (Chia-tai Tianqing)TQ-B3525治疗复发/难治性滤泡性淋巴瘤（FL）的单臂、多中心II期临床试验
[Translation] A single-arm, multicenter phase II clinical trial of TQ-B3525 in the treatment of relapsed/refractory follicular lymphoma (FL)
Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
比较TQB2303与美罗华分别联合CHOP在弥漫性大B初治患者中疗效及安全性的临床研究
[Translation] A clinical study comparing the efficacy and safety of TQB2303 and Rituximab combined with CHOP in treatment-naive patients with diffuse large B-cell tumors
100 Clinical Results associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
100 Deals associated with Rituximab biosimilar (Chia-tai Tianqing)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| CD20 positive Diffuse Large B-Cell Lymphoma | CN | 26 May 2023 | |
| Chronic Lymphocytic Leukemia | CN | 26 May 2023 | |
| Follicular Lymphoma | CN | 26 May 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD20 positive Non-Hodgkin Lymphoma | Phase 2 | CN | 01 May 2017 | |
| CD30 positive Non-Hodgkin Lymphoma | Phase 2 | CN | 01 May 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free